MYLERAN IN THE TREATMENT OF CHRONIC GRANULOCYTIC LEUKEMIA

5 May 1956

journal article
research article
Published by American Medical Association (AMA) in JAMA

Vol. 161 (1) , 54-56
https://doi.org/10.1001/jama.1956.62970010006015b

Abstract

Myleran (1,4-dimethanesulphonyloxybutane) was reported by Haddow and Timmis¹in 1953 to be an active agent against the Walker rat carcinoma 256. Their experimental studies further disclosed that this compound, unlike nitrogen mustard or roentgen rays, induced depression of granulopoiesis without depressing lymphopoiesis. These results stimulated clinical trials by investigators in England²and the United States³that subsequently demonstrated that Myleran would produce remissions in patients with chronic granulocytic leukemia. We became interested in this drug not only because the reported results of treatment appeared encouraging but also because its ease of administration on an outpatient basis and its apparent freedom from side-effects offered obvious advantages over x-ray therapy. Our results confirm those already reported. Methods and Results Ten patients with chronic granulocytic leukemia were treated with Myleran. Historical data and dosage are summarized in table 1. In all cases the diagnosis was substantiated by clinical examination and

Keywords

This publication has 0 references indexed in Scilit: